塞来昔布短期治疗对结肠癌患者胃泌素、VEGF水平的影响

Effect of Short-term Treatment with Celecoxib on Gastrin and VEGF in Patients with Colon Cancer

[目的]探讨选择性COX-2抑制剂塞来昔布对结肠癌患者胃泌素、血管内皮生长因子（VEGF）水平的影响及对结肠癌的防治作用.[方法]42例结肠癌和24例结肠腺瘤患者,予塞来昔布400 mg每天两次,连续服药2周.治疗前后放射免疫法检测血清胃泌素、ELISA法检测血浆VEGF水平的变化.[结果]①治疗前结肠癌组和结肠腺瘤组血清胃泌素分别为（108.3±23.4）ng/L、（113.3±27.4）ng/L,治疗后分别降为（81.6±19.3）ng/L、（87.7±20.8） ng/L,有统计学差异（P0.05）.[结论]塞来昔布可降低结肠癌和结肠腺瘤患者胃泌素水平,并可能影响VEGF水平,从而发挥抑制结肠癌、结肠腺瘤生长的作用.

[Objective]To observe the effect of selective COX-2 inhibitor celecoxib on gastrin and vascular endothelial growth factor（VEGF） in colon cancer and explore its role in the prevention and treatment of colon cancer. [Methods] Forty two patients with colon cancer and 24 patients with colonic adenoma were given celecoxib 400mg twice daily for 2 weeks. The changes of serum gastrin and VEGF before and after treatment were measured by radioimmunoassay（RIA） and ELISA, respectively. [Results] The level of gastrin in colon cancer group and colonic adenoma group were 108.3- 23.4ng/L and 113. 3＋27. 4 ng/L, respectiVely before treatment, and reduced to 81.6 ＋19.3ng/L and 87.7 ＋ 20.8, respectively after treatment, and there was significant difference between before and after treatment（ P 〈0.05）, but there was no significant difference between two groups. After treatment, VEGF level in two groups decreased, but there was no significant difference（ P 〈0.05）. [Conclusion]Celecoxib can reduce gastrin level in patients with colon cancer and colon adenomas and may affect VEGF level, which play the role of inhibiting the growth of colon cancer and colon adenoma.